Global Urinary Incontinence Market Research Report, Analysis, Opportunities, Forecast, Revenue, Trends, Value : Ken Research
Urinary incontinence is a symptom of general lifestyle habits resulting in the loss of bladder control which leads to involuntary urination. The severity ranges from occasionally leaking urine on coughing or sneezing to having an urge to urinate that is so sudden and strong that you cannot get to a toilet in time. To know more, click on the link below: https://www.kenresearch.com/healthcare/general-healthcare/urinary-incontinence-global-clinical/150992-91.html Contact Us: Ken Research Ankur Gupta, Head Marketing & Communications sales@kenresearch.com +91-9015378249
Urinary incontinence is a symptom of general lifestyle habits resulting in the loss of bladder control which leads to involuntary urination. The severity ranges from occasionally leaking urine on coughing or sneezing to having an urge to urinate that is so sudden and strong that you cannot get to a toilet in time. To know more, click on the link below:
https://www.kenresearch.com/healthcare/general-healthcare/urinary-incontinence-global-clinical/150992-91.html
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
sales@kenresearch.com
+91-9015378249
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
• Mirabegron, marketed in the US as Myrbetriq, is a medication that relaxes the bladder muscles and<br />
can increase the amount of urine the bladder can hold. It may also increase the amount a person is<br />
able to urinate at one time, emptying the bladder more completely. This drug reacts with other<br />
medication and recent experimentation has led to some developments in this respect. In May 2018,<br />
Tokyo based Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has<br />
approved a supplemental New Drug Application (sNDA) for the use of mirabegron in combination<br />
with the muscarinic antagonist, solifenacin succinate for the treatment of overactive bladder (OAB)<br />
with symptoms of urinary incontinence. Astellas Pharma Inc. is a Japanese company dedicated to<br />
improving the health of people around the world through the provision of innovative and reliable<br />
pharmaceutical products with urology being one of its focus sectors. The experts of their urology<br />
department believe that OAB patients may have symptoms that may not be fully managed by their<br />
current treatment but with the FDA approval of Myrbetriq in combination with solifenacin<br />
succinate, Astellas will be able to offer an additional treatment option to such people. These results<br />
have been based on data from the global Phase 3 SYNERGY 1, SYNERGY 2 and BESIDE studies. These<br />
studies had evaluated combination therapy with mirabegron and solifenacin succinate. These<br />
results are also proving safe as a controlled clinical safety study did not demonstrate increased<br />
urinary retention in Myrbetriq patients however, there have been other side effects noted.
Change language